FDA approves Ryzneuta by Evive Biotech for reducing febrile neutropenia in cancer patients
Evive Biotech, a global biopharmaceutical company and a subsidiary of Yifan Pharmaceutical Co. Ltd., along with New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., announced the U.S. Food and Drug Administration (FDA) approval of Ryzneuta (Efbemalenograstim alfa). The medication is indicated to decrease the incidence of infection as manifested by febrile […]